WordPress database error: [Can't create table `u102800555_cTMLC`.`wp_icwp_wpsf_ip_meta` (errno: 150 "Foreign key constraint is incorrectly formed")]
CREATE TABLE `wp_icwp_wpsf_ip_meta` ( id int(11) UNSIGNED NOT NULL AUTO_INCREMENT COMMENT 'Primary ID', ip_ref int(11) UNSIGNED NOT NULL COMMENT 'Foreign Key For Primary ID', asn int(10) UNSIGNED NOT NULL DEFAULT 0 COMMENT 'ASN', country_iso2 char(2) NOT NULL DEFAULT '' COMMENT 'Country Code ISO 3166-1 alpha-2', pc_is_proxy tinyint(1) UNSIGNED NOT NULL DEFAULT 0 COMMENT 'ProxyCheck: Is Proxy?', geo_updated_at int(15) UNSIGNED NOT NULL DEFAULT 0 COMMENT 'Geolocation data updated at', pc_last_check_at int(15) UNSIGNED NOT NULL DEFAULT 0 COMMENT 'ProxyCheck last lookup at', updated_at int(15) UNSIGNED NOT NULL DEFAULT 0 COMMENT 'Last Updated', created_at int(15) UNSIGNED NOT NULL DEFAULT 0 COMMENT 'Created', deleted_at int(15) UNSIGNED NOT NULL DEFAULT 0 COMMENT 'Soft Deleted', PRIMARY KEY (id), FOREIGN KEY (ip_ref) REFERENCES wp_icwp_wpsf_ips(id) ON DELETE CASCADE ON UPDATE CASCADE ) DEFAULT CHARACTER SET utf8mb4 COLLATE utf8mb4_unicode_520_ci;

WordPress database error: [Can't create table `u102800555_cTMLC`.`wp_icwp_wpsf_ip_meta` (errno: 150 "Foreign key constraint is incorrectly formed")]
CREATE TABLE `wp_icwp_wpsf_ip_meta` ( id int(11) UNSIGNED NOT NULL AUTO_INCREMENT COMMENT 'Primary ID', ip_ref int(11) UNSIGNED NOT NULL COMMENT 'Foreign Key For Primary ID', asn int(10) UNSIGNED NOT NULL DEFAULT 0 COMMENT 'ASN', country_iso2 char(2) NOT NULL DEFAULT '' COMMENT 'Country Code ISO 3166-1 alpha-2', pc_is_proxy tinyint(1) UNSIGNED NOT NULL DEFAULT 0 COMMENT 'ProxyCheck: Is Proxy?', geo_updated_at int(15) UNSIGNED NOT NULL DEFAULT 0 COMMENT 'Geolocation data updated at', pc_last_check_at int(15) UNSIGNED NOT NULL DEFAULT 0 COMMENT 'ProxyCheck last lookup at', updated_at int(15) UNSIGNED NOT NULL DEFAULT 0 COMMENT 'Last Updated', created_at int(15) UNSIGNED NOT NULL DEFAULT 0 COMMENT 'Created', deleted_at int(15) UNSIGNED NOT NULL DEFAULT 0 COMMENT 'Soft Deleted', PRIMARY KEY (id), FOREIGN KEY (ip_ref) REFERENCES wp_icwp_wpsf_ips(id) ON DELETE CASCADE ON UPDATE CASCADE ) DEFAULT CHARACTER SET utf8mb4 COLLATE utf8mb4_unicode_520_ci;

3 Pharma Stocks to Sell in February Before They Crash and Burn - Stock Market Latest

The pharma industry has developed some real blockbusters between novel vaccines and weight loss drugs over the past few years. This has increasingly led investors to view pharma stocks as a promising growth industry after years of underperformance, but many are top pharma stocks to sell.

Pharma remains a tricky field where intense competition and limited product patent lives curtail profitability. Particularly in the case of these three pharma stocks to sell, investors have built up expectations substantially higher than warranted, given their outlooks today.

Eli Lilly (LLY)

Eli Lilly (NYSE:LLY) has been on a breathtaking run. LLY stock is now up 440% over the past five years.

The company has enjoyed tremendous success thanks to its drugs targeting diabetes and obesity. In recent years, this has been one of the biggest categories of emerging pharma products. Eli Lilly is at the forefront; it has grown its total revenues from $21 billion in 2018 to an estimated $34 billion for the full year of 2023.

That growth will likely continue as Lilly expands its role in the weight loss space. In November, for example, the FDA approved Zepbound (tirzepatide) for chronic weight management.

Investors are extrapolating that Eli Lilly’s growth will continue seemingly exponentially. However, the valuation has become detached from reality, with LLY stock up to over 100 times 2023 earnings. It’s not sustainable to have the stock price quintuple while revenues have less than doubled over the same period. LLY stock will fall sharply at the first sign of a weight loss drug category slowdown.

BioNTech SE (BNTX)

BioNTech SE (NASDAQ:BNTX) commercializes immunotherapies for cancer and other infectious diseases. Its pipeline largely consists of clinical-stage products targeting various types of cancer, including melanoma, prostate and head and neck cancers.

Until 2020, BioNTech was a small firm with virtually no operating revenues. However, the firm’s fortunes changed with the advent of the COVID-19 vaccine. BioNTech partnered with Pfizer (NYSE:PFE), and the two jointly developed one of the leading vaccines for that disease. BioNTech continues to generate revenues from each new formulation of that vaccine.

However, interest in COVID-19 vaccines has fallen sharply. To that point, BioNTech’s revenues plunged from $21.6 billion in 2021 to less than $5 billion in 2023 and are set to fail again in 2024. The company’s profitability has largely evaporated, with analysts forecasting a 93x forward P/E ratio based on projected 2024 earnings. So far, BioNTech has struggled to turn its vaccine profits into a more recurring revenue stream, which could lead to a sharp downside in its share price.

Merck (MRK)

Since November 28th, shares of Merck (NYSE:MRK) have soared 25%. That’s an incredible move for a pharma company with a market capitalization of $320 billion.

The company has a leading cancer drug, Keytruda, that analysts are getting increasingly excited about. If it lives up to expectations, it could be a blockbuster drug delivering billions of dollars annually in revenues.

However, we must ask how much value a successful ramp-up in Keytruda would be worth, given that Merck has added about $60 billion in market cap over the past two months. At this point, Keytruda’s success already seems baked into the price and then some.

To that point, Morningstar’s Damien Conover believes MRK stock is significantly overvalued. He assigns a fair value of just $103 per share compared to the current $126 stock price. In addition to the high valuation today, he sees rising competition in oncology as a considerable risk to Merck’s intermediate-term outlook.

On the date of publication, Ian Bezek did not have (either directly or indirectly) any positions in the securities mentioned in this article. The opinions expressed in this article are those of the writer, subject to the InvestorPlace.com Publishing Guidelines.

Ian Bezek has written more than 1,000 articles for InvestorPlace.com and Seeking Alpha. He also worked as a Junior Analyst for Kerrisdale Capital, a $300 million New York City-based hedge fund. You can reach him on Twitter at @irbezek.

Source link

Share with your friends!

Products You May Like

Leave a comment

Your email address will not be published. Required fields are marked *

Get the latest stocks updates
straight to your inbox

Subscribe to our mailing list and get interesting stuff and updates to your email inbox.

Thank you for subscribing.

Something went wrong.